Govind Babu K, Attili Venkata Satya Suresh, Bapsy P P, Anupama G
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, 560 029, India.
Int Ophthalmol. 2007 Feb;27(1):43-4. doi: 10.1007/s10792-007-9038-9. Epub 2007 Apr 5.
Imatinib is presently the commonest prescribes drug for patients of chronic myelogenous leukemia (CML) in chronic phase (CP) worldwide. Its ocular side effects are little known. Optic neuritis caused by this drug has not been reported (Medline search). We describe perhaps the first case of optic neuritis caused by this drug.
伊马替尼目前是全球慢性期慢性髓性白血病(CML)患者最常用的处方药。其眼部副作用鲜为人知。该药物引起的视神经炎尚未见报道(医学文献数据库检索)。我们描述了可能是首例由该药物引起的视神经炎病例。